Anti-ganglioside antibody-mediated neuronal cytotoxicity and its protection by intravenous immunoglobulin: Implications for immune neuropathies

G. Zhang, Pablo Lopez, C. Y. Li, N. R. Mehta, J. W. Griffin, Ronald Lee Schnaar, Kazim A. Sheikh

Research output: Contribution to journalArticle

Abstract

Antibodies against GD1a, GM1 and related gangliosides are frequently present in patients with the motor variant of Guillain-Barré syndrome (GBS), and their pathological role in this variant of GBS is now widely accepted. However, two basic issues related to anti-ganglioside antibody-mediated neural injury are not completely resolved: (i) some anti-ganglioside antibodies can cross-react with glycoproteins and therefore the nature of antigens targeted by these antibodies is not well established; and (ii) although pathological studies suggest that complement activation occurs in GBS, experimental data for the role of complement remain inconclusive. To address these issues, we developed and characterized a simple anti-ganglioside antibody-mediated cytotoxicity assay. Our results demonstrate first, that both GBS sera containing anti-ganglioside antibodies and monoclonal anti-ganglioside antibodies cause neuronal cell lysis by targeting specific cell surface gangliosides, and secondly, that this cell lysis is complement dependent. In this assay, the GD1a cell membrane pool appears to be more susceptible to anti-ganglioside antibody-mediated injury than the GM1 pool. Further, human intravenous immunoglobulin (IVIg), now a standard treatment for GBS, significantly decreased cytotoxicity in this assay. Our data indicate that the mechanisms of IVIg-mediated protection in this assay include anti-idiotypic antibodies and downregulation of complement activation. This simple cytotoxicity assay can potentially be used for screening of (i) pathogenic anti-ganglioside antibodies in patients with immune-mediated neuropathies; and (ii) new/experimental therapies to prevent anti-ganglioside antibody-mediated neural injury.

Original languageEnglish (US)
Pages (from-to)1085-1100
Number of pages16
JournalBrain
Volume127
Issue number5
DOIs
StatePublished - May 2004

Fingerprint

Gangliosides
Intravenous Immunoglobulins
Anti-Idiotypic Antibodies
Complement Activation
Wounds and Injuries
G(M1) Ganglioside
Investigational Therapies
Antibodies
Glycoproteins
Down-Regulation
Monoclonal Antibodies
Cell Membrane
Antigens

Keywords

  • Acute motor axonal neuropathy
  • Anti-ganglioside antibodies
  • Cytotoxicity assay
  • Guillain-Barré syndrome
  • IVIg

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Anti-ganglioside antibody-mediated neuronal cytotoxicity and its protection by intravenous immunoglobulin : Implications for immune neuropathies. / Zhang, G.; Lopez, Pablo; Li, C. Y.; Mehta, N. R.; Griffin, J. W.; Schnaar, Ronald Lee; Sheikh, Kazim A.

In: Brain, Vol. 127, No. 5, 05.2004, p. 1085-1100.

Research output: Contribution to journalArticle

@article{eb819d9c70c44b3db11016b09e7de006,
title = "Anti-ganglioside antibody-mediated neuronal cytotoxicity and its protection by intravenous immunoglobulin: Implications for immune neuropathies",
abstract = "Antibodies against GD1a, GM1 and related gangliosides are frequently present in patients with the motor variant of Guillain-Barr{\'e} syndrome (GBS), and their pathological role in this variant of GBS is now widely accepted. However, two basic issues related to anti-ganglioside antibody-mediated neural injury are not completely resolved: (i) some anti-ganglioside antibodies can cross-react with glycoproteins and therefore the nature of antigens targeted by these antibodies is not well established; and (ii) although pathological studies suggest that complement activation occurs in GBS, experimental data for the role of complement remain inconclusive. To address these issues, we developed and characterized a simple anti-ganglioside antibody-mediated cytotoxicity assay. Our results demonstrate first, that both GBS sera containing anti-ganglioside antibodies and monoclonal anti-ganglioside antibodies cause neuronal cell lysis by targeting specific cell surface gangliosides, and secondly, that this cell lysis is complement dependent. In this assay, the GD1a cell membrane pool appears to be more susceptible to anti-ganglioside antibody-mediated injury than the GM1 pool. Further, human intravenous immunoglobulin (IVIg), now a standard treatment for GBS, significantly decreased cytotoxicity in this assay. Our data indicate that the mechanisms of IVIg-mediated protection in this assay include anti-idiotypic antibodies and downregulation of complement activation. This simple cytotoxicity assay can potentially be used for screening of (i) pathogenic anti-ganglioside antibodies in patients with immune-mediated neuropathies; and (ii) new/experimental therapies to prevent anti-ganglioside antibody-mediated neural injury.",
keywords = "Acute motor axonal neuropathy, Anti-ganglioside antibodies, Cytotoxicity assay, Guillain-Barr{\'e} syndrome, IVIg",
author = "G. Zhang and Pablo Lopez and Li, {C. Y.} and Mehta, {N. R.} and Griffin, {J. W.} and Schnaar, {Ronald Lee} and Sheikh, {Kazim A.}",
year = "2004",
month = "5",
doi = "10.1093/brain/awh127",
language = "English (US)",
volume = "127",
pages = "1085--1100",
journal = "Brain",
issn = "0006-8950",
publisher = "Oxford University Press",
number = "5",

}

TY - JOUR

T1 - Anti-ganglioside antibody-mediated neuronal cytotoxicity and its protection by intravenous immunoglobulin

T2 - Implications for immune neuropathies

AU - Zhang, G.

AU - Lopez, Pablo

AU - Li, C. Y.

AU - Mehta, N. R.

AU - Griffin, J. W.

AU - Schnaar, Ronald Lee

AU - Sheikh, Kazim A.

PY - 2004/5

Y1 - 2004/5

N2 - Antibodies against GD1a, GM1 and related gangliosides are frequently present in patients with the motor variant of Guillain-Barré syndrome (GBS), and their pathological role in this variant of GBS is now widely accepted. However, two basic issues related to anti-ganglioside antibody-mediated neural injury are not completely resolved: (i) some anti-ganglioside antibodies can cross-react with glycoproteins and therefore the nature of antigens targeted by these antibodies is not well established; and (ii) although pathological studies suggest that complement activation occurs in GBS, experimental data for the role of complement remain inconclusive. To address these issues, we developed and characterized a simple anti-ganglioside antibody-mediated cytotoxicity assay. Our results demonstrate first, that both GBS sera containing anti-ganglioside antibodies and monoclonal anti-ganglioside antibodies cause neuronal cell lysis by targeting specific cell surface gangliosides, and secondly, that this cell lysis is complement dependent. In this assay, the GD1a cell membrane pool appears to be more susceptible to anti-ganglioside antibody-mediated injury than the GM1 pool. Further, human intravenous immunoglobulin (IVIg), now a standard treatment for GBS, significantly decreased cytotoxicity in this assay. Our data indicate that the mechanisms of IVIg-mediated protection in this assay include anti-idiotypic antibodies and downregulation of complement activation. This simple cytotoxicity assay can potentially be used for screening of (i) pathogenic anti-ganglioside antibodies in patients with immune-mediated neuropathies; and (ii) new/experimental therapies to prevent anti-ganglioside antibody-mediated neural injury.

AB - Antibodies against GD1a, GM1 and related gangliosides are frequently present in patients with the motor variant of Guillain-Barré syndrome (GBS), and their pathological role in this variant of GBS is now widely accepted. However, two basic issues related to anti-ganglioside antibody-mediated neural injury are not completely resolved: (i) some anti-ganglioside antibodies can cross-react with glycoproteins and therefore the nature of antigens targeted by these antibodies is not well established; and (ii) although pathological studies suggest that complement activation occurs in GBS, experimental data for the role of complement remain inconclusive. To address these issues, we developed and characterized a simple anti-ganglioside antibody-mediated cytotoxicity assay. Our results demonstrate first, that both GBS sera containing anti-ganglioside antibodies and monoclonal anti-ganglioside antibodies cause neuronal cell lysis by targeting specific cell surface gangliosides, and secondly, that this cell lysis is complement dependent. In this assay, the GD1a cell membrane pool appears to be more susceptible to anti-ganglioside antibody-mediated injury than the GM1 pool. Further, human intravenous immunoglobulin (IVIg), now a standard treatment for GBS, significantly decreased cytotoxicity in this assay. Our data indicate that the mechanisms of IVIg-mediated protection in this assay include anti-idiotypic antibodies and downregulation of complement activation. This simple cytotoxicity assay can potentially be used for screening of (i) pathogenic anti-ganglioside antibodies in patients with immune-mediated neuropathies; and (ii) new/experimental therapies to prevent anti-ganglioside antibody-mediated neural injury.

KW - Acute motor axonal neuropathy

KW - Anti-ganglioside antibodies

KW - Cytotoxicity assay

KW - Guillain-Barré syndrome

KW - IVIg

UR - http://www.scopus.com/inward/record.url?scp=2442622616&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=2442622616&partnerID=8YFLogxK

U2 - 10.1093/brain/awh127

DO - 10.1093/brain/awh127

M3 - Article

C2 - 14985267

AN - SCOPUS:2442622616

VL - 127

SP - 1085

EP - 1100

JO - Brain

JF - Brain

SN - 0006-8950

IS - 5

ER -